Literature DB >> 17032569

Update on the management of hypertension to prevent stroke.

Laura Pedelty1, Philip B Gorelick.   

Abstract

Hypertension is the leading modifiable risk factor for stroke, including first-ever and recurrent stroke. The association between blood pressure (BP) and stroke risk is continuous and may be documented as low as 115/75 mm Hg. Because of this continuum of risk, and because most strokes occur in individuals with mild hypertension or even normal BP values, we are now beginning to recognize "prehypertension" as a stage in which early recognition and intervention may confer benefit. In addition to increased risk for ischemic and hemorrhagic stroke, hypertension may be associated with increased risk of cognitive impairment. Reductions in BP are reliably associated with reduced stroke risk. Some evidence suggests that certain agents, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, may have protective effects beyond BP lowering. Overall, the degree of BP lowering is key, and therefore most classes of BP-lowering agents may be recommended at this point. Many patients with hypertension will require more than one BP-lowering agent to control BP. Lifestyle modification is appropriate at all levels of intervention. Further studies are needed to ascertain the mechanisms of benefit of different classes of antihypertensive agents in the reduction of stroke and cardiovascular disease risk.

Entities:  

Year:  2006        PMID: 17032569     DOI: 10.1007/s11940-006-0038-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  32 in total

1.  Blood pressure and stroke: an overview of published reviews.

Authors:  Carlene M M Lawes; Derrick A Bennett; Valery L Feigin; Anthony Rodgers
Journal:  Stroke       Date:  2004-04       Impact factor: 7.914

Review 2.  The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease.

Authors:  B McGuinness; S Todd; P Passmore; R Bullock
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

4.  Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials.

Authors:  X Xin; J He; M G Frontini; L G Ogden; O I Motsamai; P K Whelton
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

5.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.

Authors:  F M Sacks; L P Svetkey; W M Vollmer; L J Appel; G A Bray; D Harsha; E Obarzanek; P R Conlin; E R Miller; D G Simons-Morton; N Karanja; P H Lin
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

6.  Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline.

Authors:  Larry B Goldstein; Robert Adams; Mark J Alberts; Lawrence J Appel; Lawrence M Brass; Cheryl D Bushnell; Antonio Culebras; Thomas J Degraba; Philip B Gorelick; John R Guyton; Robert G Hart; George Howard; Margaret Kelly-Hayes; J V Ian Nixon; Ralph L Sacco
Journal:  Stroke       Date:  2006-05-04       Impact factor: 7.914

Review 7.  Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review.

Authors:  Philip B Gorelick
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

Authors:  Joachim Schrader; Stephan Lüders; Anke Kulschewski; Frank Hammersen; Kerstin Plate; Jürgen Berger; Walter Zidek; Peter Dominiak; Hans Christoph Diener
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.